Biosolutions portofolio

At Aramis, our portfolio is not limited to markets or products. It is guided by a simple question: what do plants make possible? Every biosolution we develop leverages the unique properties of our plant-based platform to address real needs in health, agriculture, food, and other high-impact sectors.

Human health

Unique speed, flexibility, and scalability to develop and produce vaccines, antibodies, and other therapeutics, while ensuring rapid response to health emergencies.

  • Clinically validated at scale with more than 21 clinical studies completed and more than 50,000 participants.
  • First commercial regulatory approval for a vaccine. Covifenz® was approved by Health Canada and produced commercially.
  • Lipid particle technology combining immunological benefits with plant-based manufacturing.
  • Demonstrated ability to develop and produce a wide range of vaccines, including influenza, COVID-19, rotavirus, norovirus, and EV71, as well as therapeutic antibodies and other complex biological proteins.

Animal health

  • The great versatility of the plant-based platform allows the manufacture of complex and diversified biological products for animal health, including veterinary vaccines, immunomodulators, functional probiotics and bioactive nutritional additives.
  • Plant-based alternative to cell culture and messenger RNA.
  • Reduced production costs allowing access to a new generation of vaccines and biological treatments on a large scale.

Agriculture

  • Unique capability to simultaneously produce multiple proteins and metabolites in a single plant, creating an opportunity to combine products within the same plant, production batch, and manufacturing platform.
  • Ideal for the production of several synergistic active ingredients – up to several dozen at the same time.
  • Alternative to microbial or chemical synthesis products.
  • Smart biofertilizers and biostimulants.
  • Biopesticides & biofungicides.

Other areas of application